BriaCell’s Bria-OTS mechanism of action study published by JCI Insight

BriaCell (BCTX) Therapeutics announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute, NCI, the US federal government’s principal agency for cancer research and training, has been published at JCI Insight. “These data are consistent with the encouraging clinical results we recently reported in our Phase 1/2a study in metastatic breast cancer and provide important insights into the mechanism of action of our cellular immunotherapy platform technology,” added Dr. William V. Williams, BriaCell’s President and CEO.